Advanced search
Publication Cover
Journal of Dermatological Treatment Volume 33, 2022 - Issue 7
Submit an article Journal homepage
198
Views
1
CrossRef citations to date
0
Altmetric
Short Report

Biologic use in hidradenitis suppurativa: patient perspectives and barriers

Devea R. Dea Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, Buffalo, NY, USAORCID Iconhttps://orcid.org/0000-0003-4921-2066
ORCID Icon,
Terri Shihb David Geffen School of Medicine, University of California, Los Angeles, CA, USA
,
Denise Fixsenc HS Connect, Puyallup, WA, USA
,
Brindley Brooksc HS Connect, Puyallup, WA, USA
,
Jennifer L. Hsiaod Department of Dermatology, University of Southern California, Los Angeles, CA, USAORCID Iconhttps://orcid.org/0000-0002-8843-3630
ORCID Icon &
Vivian Y. Shie Department of Dermatology, University of Arkansas for Medical Sciences, Little Rock, AR, USACorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0002-7510-9428
ORCID Icon
Pages 3060-3062 | Received 13 Apr 2022, Accepted 24 May 2022, Published online: 10 Jul 2022

References

  • Maarouf M, Clark AK, Lee DE, et al. Targeted treatments for hidradenitis suppurativa: a review of the current literature and ongoing clinical trials. J Dermatolog Treat. 2018;29(5):441–449.
  • Bechara FG, Podda M, Prens EP, et al. Efficacy and safety of adalimumab in conjunction with surgery in moderate to severe hidradenitis suppurativa: the SHARPS randomized clinical trial. JAMA Surg. 2021;156(11):1001–1009.
  • Marzano AV, Genovese G, Casazza G, et al. Evidence for a “window of opportunity” in hidradenitis suppurativa treated with adalimumab: a retrospective, real-life multicentre cohort study. Br J Dermatol. 2021;184(1):133–140.
  • Seivright JR, Thompson A, Hamzavi I, et al. Hidradenitis suppurativa specialty clinics in the USA. Skin Appendage Disord. 2021;7(5):359–362.
  • Fernandez JM, Madsen S, Krase JM, et al. Classification and mitigation of negative injection experiences with biologic medications. Dermatologic Therapy [Internet]. 2020;33(2). DOI:10.1111/dth.13240.
  • Caposiena Caro RD, Chiricozzi A, Sechi A, et al. Factors related to the onset and recurrence of flares in hidradenitis suppurativa patients treated with adalimumab. Ital J Dermatol Venerol. 2022;157:137–141.
  • Caposiena Caro RD, Cannizzaro MV, Tartaglia C, et al. Clinical response rate and flares of hidradenitis suppurativa in the treatment with adalimumab. Clin Exp Dermatol. 2020;45(4):438–444.
  • Bettoli V, Manfredini M, Calamo G, et al. Long-term adalimumab treatment of hidradenitis suppurativa: Results and practical insights from a real-life experience. Dermatol Ther. 2018;31(6):e12737.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.